PTU - Polskie Towarzystwo Urologiczne
home page
current numbers
archival numbers
list of articles:
list przewodni/covering letter
editor
Scientific Committee
publisher
subscription
advertising
important links

Preoperative systemic chemoptherapy CMV (cisplatin, methotrexate, vinblastin) in infiltrating cancer of the urinary bladder
Article published in Urologia Polska 1992/45/4.

authors

Andrzej Stokłosa, Jan Szymanowski, Ewa Koźmińska
Z Oddziału Urologii Szpitala Bielańskiego w Warszawie Ordynator: dr n. med. J. Szymanowski

summary

Presented here is a group of 41 patients with bladder cancer (T2-T3) in whom neo--adjuvant preoperative systematic chemotherapy was applied. The paper discusses the treatment results, methods of surgery and toxicity. Complete response to treatment (CCR) was observed in 12 (29.0%) patients, partial response (PCR) in 11 (27.0%) patients, no response (STAB) in 10 (24.0%) patients and progress of cancer was observed in 6 (15.0%) patients. Two (5.0%) patients died because of the toxicity of CMV

references

  1. 1. Borkowski A., Michalec J., Pawiński A., Gajl D., Madej G., Krzeski T.: Wstępne doświadczenia w chemioterapii systemowej M-VAC w leczeniu chorych z zaawansowanym rakiem pęcherza (T2-T4). Urol. Pol., 1991, XLIV, 3, 149. —
  2. 2. Koźmińska E., Szymanowski J., Stokłosa A.: Systemic CMV for invasive bladder cancer. Eur. Urol., 1990, 18/S1/90, Abstracts of IXth Congress of EAU Amsterdam, June 13- 16, 1990, 615. —
  3. 3. Klimberg I. W., Wajsman Z.: Treatment for muscle invasive carcinoma of the bladder. J. Urol., 1986, 136, 6, 169. —
  4. 4. Meyers F. J., Palmer J. M., Freiha F. S., Harker E. G., Shortliffe L. D., HanniganJ., McWhriter K., Toni F. M.: The fate of the bladder in patients with metastatic bladder cancer treated with cisplatin, methotrexate and vinblastine: a Northern California Oncology Group Study. J. Urol., 1985, 134, 6, 1118. —
  5. 5. Newling D. W. W., Denis L. J.: Adjuyant and neo--adjuvant chemotherapy in bladder cancer. Academic Journals, Urology, June 1990, 2, 4, The Netherlands. —
  6. 6. Scher H. I., Yagoda A., Herr H. W., Sternberg C. N., Bosi G., Morse M. J., Sogani P. C, Watson R. C, Dershaw D. D., Reuter V., Geller N., Hollander P. S., Vaughan E. D. Jr., Whitmore W. F. Jr., Fair W. R.: Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J. Urol., 1988, 139, 3, 470. —
  7. 7. Scher H. /.: Chemotherapy for invasive bladder tumors: neoadjuvant vs adjuyant. Sem. Oncol., J. Urol., w druku. —
  8. 8. Splinter T. A. W., Scher I. H., Denis L., Bukowski R., Simon S., Klimberg I., Soloway M., Yogelzang N. J., van Tinteren H., Herr H. European Organization for Reserch on Treatment of Cancer-Genitourinary Group: The Prognostic value of the pathological response to Combination chemotherapy before cystectomy in patients with invasive bladder cancer. J. Urol., 1992, 147, 3, 606. —
  9. 9. Szymanowski J.: Sprawozdanie z pobytu naukowego w Stanach Zjednoczonych Ameryki Północnej od 18.X.1986 do 17.XI.1986 oraz udziału w sympozjum onkologicznym „1986 Medical Oncology Grand Rounds\\\" w dniach 14 i 15.XII.1986. Urol. Pol., 1988, 41, 1, 71. —
  10. 10. Wajsman Z.: Chemotherapy and irradiation for infiltrative bladder cancer: bladder — sparing procedure. AUA Today, 1988 1, 3, 14.

correspondence

lek. med. Andrzej Stokłosa 01-391 Warszawa, ul. Anieli Krzywoń 4 m. 13